Rethinking EZH2 Inhibition: A Priming Strategy for EGFR-targeted Therapy in Bladder Cancer. Nossing C, Ertl IE, Englinger B. Eur Urol Oncol 2026 Aug 25:S2588-9311(26)00236.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nossing C, Ertl IE, Englinger B. Rethinking EZH2 Inhibition: A Priming Strategy for EGFR-targeted Therapy in Bladder Cancer. Eur Urol Oncol 2026 Aug 25:S2588-9311(26)00236.
PMID: 42642273